(1-(trifluoromethyl)cyclobutyl)methanamine hydrochloride | 1803604-67-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: (1-(trifluoromethyl)cyclobutyl)methanamine hydrochloride
• 英文别名: [1-(Trifluoromethyl)cyclobutyl]methanamine hydrochloride；[1-(trifluoromethyl)cyclobutyl]methanamine;hydrochloride
• CAS: 1803604-67-2
• 化学式: C₆H₁₀F₃N*ClH
• mdl: MFCD28135625
• 分子量: 189.608
• InChiKey: HSTWTAYNCJVTLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.34
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1-(trifluoromethyl)cyclobutyl)methanamine hydrochloride 、 2-(2-chloro-4-phenylpyridin-3-yl)-3,4,6,7-tetrahydropyrano[3,4-d]imidazole 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 以30 %的产率得到4-phenyl-3-(3,4,6,7-tetrahydropyrano[3,4-d]imidazol-2-yl)-N-((1-(trifluoromethyl)cyclobutyl)methyl)pyridin-2-amine
  参考文献：
  名称：

  WO2023/49364

  摘要：

  公开号：

文献信息

• 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
  申请人：Janssen Pharmaceutica NV

  公开号：US10975057B2

  公开（公告）日：2021-04-13

  The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明包括式 I 的化合物。 其中 R1、Q、R3、R4、R5、R6、A1 和 A2 的定义见说明书。 本发明还包括一种治疗或改善 ROR-γ-t 介导的综合征、紊乱或疾病的方法，其中综合征、紊乱或疾病选自由类风湿性关节炎、银屑病关节炎和银屑病组成的组。本发明还包括一种通过施用治疗有效量的至少一种式 I 化合物来调节哺乳动物体内 RORγt 活性的方法。
• 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT
  申请人：Janssen Pharmaceutica NV

  公开号：EP3806958A1

  公开（公告）日：2021-04-21
• [EN] 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT<br/>[FR] 6-AMINOPYRIDIN-3-YL PYRAZOLES EN TANT QUE MODULATEURS DE RORYT
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019244001A1

  公开（公告）日：2019-12-26

  The present invention comprises compounds of Formula I. Formula I wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-ϒ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORϒt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
• COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS
  申请人：[en]SEPTERNA, INC.

  公开号：WO2024155601A1

  公开（公告）日：2024-07-25

  Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods of using them for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis.